secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001193125-26-107314
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin discontinues VOXZOGO trials in Turner, SHOX, ACAN after SCFE safety events
--------------------------------------------------------------------------------

- Discontinued dosing and enrollment in Phase 2 CANOPY trials for Turner syndrome, SHOX-deficiency, and ACAN-deficiency.
- Decision follows slipped capital femoral epiphysis (SCFE) events in two investigator-sponsored trials; SCFE not seen in BioMarin's own trials or in >5,000 achondroplasia patients.
- Phase 2 CANOPY trials for Noonan syndrome and idiopathic short stature (ISS) without ACAN-deficiency will continue as planned.
- Over 10,000 patient-years of safety data in achondroplasia shows no SCFE cases; VOXZOGO remains approved for achondroplasia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526107314/0001193125-26-107314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526107314/d114815d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-107314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer